FutureFemHealth

FutureFemHealth

Home
Work with us / Advertise
CensHERship
Archive
About
💌 Menstrual blood diagnostics | $55m for overlooked heart disease | Clair moves out of stealth | Calla Lily lands Merck
The global weekly briefing on women's health innovation and Femtech
 • Anna O'Sullivan
Menstrual blood diagnostics in 2026: what's changing - and what we're tracking
FFHi - Brief: Why menstrual blood diagnostics are entering the mainstream — and what will determine whether they scale
 • Anna O'Sullivan
Clair emerges from stealth with plans to launch continuous hormone tracking wearable
Tracks hormonal dynamics in real time, without relying on blood draws, urine tests or needles
 • Anna O'Sullivan
Breaking down silos: why women’s health data needs a different future
As women’s health data explodes across apps, wearables and clinical systems, fragmentation — not scarcity — may be the biggest barrier to meaningful…
 • Anna O'Sullivan and Sophie Louise Feith
Calla Lily secures Merck as first industry partner for intravaginal drug delivery platform
Strategic partnership will support the continued development of Callavid®, its novel intravaginal drug delivery platform
 • Anna O'Sullivan
Wellcome Leap launches $55m program to tackle overlooked heart disease in women
Jointly funded with Pivotal and supported by the British Heart Foundation
 • Anna O'Sullivan
From NHS entry to US acquisition: how Fetal Pillow scaled and exited as a women’s health device
What the Fetal Pillow journey reveals about NHS adoption, FDA clearance, U.S hospital sales and how acquirers actually source companies to buy
 • Anna O'Sullivan
Garmin smartwatch data integrated into women's metabolic health platform Hello Inside
Collaboration enables personalised, longitudinal monitoring for women throughout hormonal transitions
 • Anna O'Sullivan
Onsite Women’s Health launches AI-enabled mammography programme to surface cardiovascular risk
Designed to identify potential cardiovascular risk during routine screening mammograms.
 • Anna O'Sullivan
💌 Issue 132: Midi Health's $100m raise | $50m for sports & performance institute | EU women's health strategy a step closer
The global weekly briefing on women's health innovation and Femtech
 • Anna O'Sullivan
Menotracker launches menopause tracking app with pseudonymous data architecture
Approach is intended to reduce the risk of sensitive menopause data being shared, sold, or disclosed, either commercially or through legal processes.
 • Anna O'Sullivan
Midi Health raises $100m Series D at $1bn valuation
Midi now serves 25,000 patients every week.
 • Anna O'Sullivan
© 2026 FutureFemHealth · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture